Loading stock data…
RenovoRx, Inc. (RNXT)
$2.20-0.19 (-7.95%)
Market ClosedLast close Sep 8
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
RenovoRx, Inc. in the Healthcare sector is trading at $2.20 with a market capitalization of $99M. Wall Street consensus targets $7.12 (4 analysts), implying a +223.9% move over the next 12 months. The stock is currently 15% below its 52-week high of $2.59, remaining 120.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +223.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $909,000↑ | $563,000↑ | $238,000↓ | $266,000↓ | $422,000 |
| Gross Profit | $766,000↑ | $479,000↑ | $210,000↓ | $213,000↓ | $270,000 |
| Operating Income | -$3.35M↑ | -$3.47M↑ | -$3.52M↓ | -$3.20M↓ | -$2.68M |
| Net Income | -$2.91M↑ | -$3.52M↓ | -$2.94M↓ | -$2.91M↓ | -$2.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$99.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-136.82%
Volume
Today's trading volume
1.21M
Recent News
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
RenovoRx (NASDAQ:RNXT) will use its H. C.
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RenovoRx (NASDAQ:RNXT) executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company’s Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTradin
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
RenovoRx Inc (RNXT) reports a 115% year-over-year revenue surge, driven by commercial adoption and full enrollment in its pivotal TIGERPAC trial.
RenovoRx, Inc. Q2 2026 Earnings Call Summary
Moby summary of RenovoRx, Inc.'s Q2 2026 earnings call
RenovoRx Q2 Earnings Call Highlights
RenovoRx (NASDAQ:RNXT) reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer. For the quarter ended June 30, 2026, the company generated revenue of $909,000, up approximately 61% from $563,